BPH Energy’s investment, Cortical Dynamics, advances brain monitoring technology

BPH Energy ASX Investee Cortical Dynamics Brain Anesthesia Response Monitor BARM Technology EEG Electrical Activity Function
BPH Energy has a 17.7% stake in Cortical Dynamics.

BPH Energy (ASX: BPH) has provided an update on its investee Cortical Dynamics, which continues to take steps toward advancing its cerebral anesthesia response monitor (BARM) unit, described as an EEG brain function monitor ( electrical activity) leader in the industry.

BARM is being developed by Cortical to better detect the effect of anesthetic agents on brain activity to keep patients optimally anesthetized.

The Perth-based medical device neurotechnology company considers its BARM unit to be “the world’s most reliable, flexible and objective medical brain monitoring technology, capable of measuring both levels of unconsciousness and pain.”

Through trials and evaluations, BARM has been used in more than 200 operations worldwide in several different hospitals with positive results.

Cortical recently partnered with Austrian EEG experts ENCEVIS and the Austrian Institute of Technology AIT in an effort to further refine its BARM technology.

With more than 1,300 employees, AIT is the largest research and technology organization in Austria, with ENCEVIS as one of its divisions and specializing in EEG.

Prestigious IA Scholarship

In June 2022, Cortical won a prestigious grant from Australia’s MTPConnect BioMedTech Horizons (BMTH) program. The grant will help Cortical develop artificial intelligence and machine learning capabilities for its BARM unit.

The BMTH program was created to improve the health outcomes of Australians, while strengthening the biomedical and medical technology sector, driving jobs and business growth, and awarding the best and brightest researchers from Australia.

In the past, the program has been successful in bringing state-of-the-art medical devices to market.

Cortical has made two appointments, a full-time project manager, but most notably a world-class head of data analytics, focusing on developing a greater understanding of sedation level monitoring systems using AI such as EEG, machine learning , statistical analysis and anesthesiology

See also  Georgia Tech professor working on NASA's Artemis mission

Application areas include the optimal management of anesthesia and sedatives in the OR and ICU.

Awaiting FDA approval

Cortical has begun its Food and Drug Administration (FDA) 510K filing process for BARM in the US, with the help of Washington-based MCRA technical advisors.

The company is seeking FDA approval to begin sales of its BARM unit in the US.

Previously, BARM has already received Therapeutic Goods Administration (TGA) approval in Australia, Korea Ministry of Food and Drug Safety (MFDS) approval, and CE marking in the European Union.

US patent expands its extensive portfolio

Throughout the year, Cortical continued to expand its US IP portfolio and developed an extensive patent portfolio protecting BARM in several key brain monitoring markets.

Cortical has a competitive advantage with a strong patent position covered by five patent families and 36 granted patents.

The company already has protection in key brain monitoring markets in the UK, Australia, New Zealand and Japan.

Cortical has also obtained patents in France, Belgium, Germany, the Netherlands, Switzerland, Italy, Ireland and the People’s Republic of China.

BPH, a diversified investment firm, has a 17.7% stake in Cortical.

Leave a Comment